Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Silvaco initiated with Buy rating and $26 price target by Rosenblatt analyst, well-positioned to benefit from EDA market with strong TCAD position and growth opportunities. Needham analyst also gives Buy rating and $28 target, forecasts improved margins and revenue.
Goldman Sachs analyst Toshiya Hari reiterated a Buy rating on the shares of Nvidia with a price target of $1,200. BofA Securities analyst Vivek Arya reiterated a Buy rating on the shares and raised the price target from $1,320 to $1,500.